Parkman Healthcare Partners’s Merck MRK Stock Holding History

Parkman Healthcare Partners’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,000	Closed	-$12.4M	–	101
2024 Q2	$12.4M	Buy	+100,000	New	+$12.9M	1.66%	19

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parkman Healthcare Partners's MRK Position: Q4 2020 in Review

Parkman Healthcare Partners sold out of Merck (MRK) in Q4 2020, closing a stake of 131,874 shares — an estimated $10.4M sold.

Parkman Healthcare Partners first reported a position in MRK in Q4 2019 and held it in 4 quarters. The position peaked at $20M in Q4 2019. 2,709 funds tracked by Wall St. Rank hold MRK as of Q4 2020.

Parkman Healthcare Partners reported no remaining Merck position as of Q4 2020 after selling out during the quarter.
Parkman Healthcare Partners sold 131,874 Merck shares in Q4 2020, an estimated $10.4M.
Parkman Healthcare Partners first reported a position in Merck in Q4 2019 and held it in 4 quarters.
Parkman Healthcare Partners's Merck position peaked at $20M in Q4 2019.
2,709 funds tracked by Wall St. Rank held Merck as of Q4 2020.

Based on Parkman Healthcare Partners's 13F filing for Q4 2020, filed 12 Feb 2021.